Standout Papers

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: ... 2021 2026 2022 2024203
  1. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study (2021)
    Martin Hutchings, Rogier Mous et al. The Lancet

Immediate Impact

2 by Nobel laureates 12 from Science/Nature 53 standout
Sub-graph 1 of 23

Citing Papers

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
2025 Standout
GZMK-expressing CD8+ T cells promote recurrent airway inflammatory diseases
2025 StandoutNature
4 intermediate papers

Works of Martine E.D. Chamuleau being referenced

DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
2020
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
2019
and 1 more

Author Peers

Author Last Decade Papers Cites
Martine E.D. Chamuleau 560 675 316 649 100 1.6k
Udo Holtick 317 711 312 624 85 1.9k
Todd W. Kelley 338 320 437 616 68 1.9k
Mina L. Xu 561 755 198 675 77 2.0k
Ivana Pierri 656 593 432 746 67 2.0k
Ilseung Choi 597 672 214 894 96 1.7k
Jean‐Pierre Farcet 553 332 209 584 43 1.3k
Noemí Puig 384 504 459 386 110 1.7k
Asahi Ito 169 377 104 546 68 1.4k
Irena Frydecka 245 480 172 926 103 1.4k
Thomas Eiermann 160 424 275 1007 65 1.9k

All Works

Loading papers...

Rankless by CCL
2026